Paul J. HERGENROTHER,David A. BOOTHMAN,Joseph S. BAIR,Lifen CAO,Jinming GAO,Xiumei HUANG,Xiuquan LUO,Xinpeng MA,Zachary R. MOORE,Elizabeth I. PARKINSON
申请号：
US15834052
公开号：
US20180099002A1
申请日:
2017.12.06
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
